Inhibitory Effect of Endostar on Specific Angiogenesis Induced by Human Hepatocellular Carcinoma

Ye, Qing; Qin, Shukui; Liu, Yanhong; Jundong, Feng; Wu, Qiong; Qu, Wenshu; Yin, Xianzhen

doi:10.1155/2015/957574

Cited by 8 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To exploit the potential of endostatin as a novel therapeutic tool, a recombinant human form was developed (Endostar) [164]. This agent was demonstrated to inhibit endothelial HUVEC cell proliferation, migration, invasion, and tubulogenesis per se, or as a result of interaction with HCC cells in vitro, probably via the impairment of the Wnt/β-catenin signaling pathway [165,166]. Proteoglycan 4 (PRG4 or also called lubricin), a high molecular weight proteoglycan, is abundantly present in the synovium of joints, where it plays a role as a lubricant, thus contributing to maintaining their physiologic homeostatic state [167].…”

Section: Proteoglycans As Therapeutic Targets or Agents In Hccmentioning

confidence: 99%

Proteoglycans in Cancer: Friends or Enemies? A Special Focus on Hepatocellular Carcinoma

Dituri

Gigante

Scialpi

et al. 2022

Cancers

View full text Add to dashboard Cite

Proteoglycans are a class of highly glycosylated proteins expressed in virtually all tissues, which are localized within membranes, but more often in the pericellular space and extracellular matrix (ECM), and are involved in tissue homeostasis and remodeling of the stromal microenvironment during physiological and pathological processes, such as tissue regeneration, angiogenesis, and cancer. In general, proteoglycans can perform signaling activities and influence a range of physical, chemical, and biological tissue properties, including the diffusivity of small electrolytes and nutrients and the bioavailability of growth factors. While the dysregulated expression of some proteoglycans is observed in many cancers, whether they act as supporters or limiters of neoplastic progression is still a matter of controversy, as the tumor promoting or suppressive function of some proteoglycans is context dependent. The participation of multiple proteoglycans in organ regeneration (as demonstrated for the liver in hepatectomy mouse models) and in cancer suggests that these molecules actively influence cell growth and motility, thus contributing to key events that characterize neoplastic progression. In this review, we outline the main roles of proteoglycans in the physiology and pathology of cancers, with a special mention to hepatocellular carcinoma (HCC), highlighting the translational potential of proteoglycans as targets or therapeutic agents for the treatment of this disease.

show abstract

Section: Proteoglycans As Therapeutic Targets or Agents In Hccmentioning

confidence: 99%

Proteoglycans in Cancer: Friends or Enemies? A Special Focus on Hepatocellular Carcinoma

Dituri

Gigante

Scialpi

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…It was shown to promote the efficiency of chemotherapy during the treatment of advanced non-small cell lung cancer phase II/III clinical trials [ 97 ]. Preclinical studies of Endostar also showed anti-angiogenic effects in HCC in vitro [ 98 ] and in vivo [ 99 ], suggesting that combination therapy with Endostar could be considered for the treatment of HCC.…”

Section: Pericellular Proteoglycan: Collagen Xviii/endostatinmentioning

confidence: 99%

Proteoglycans Are Attractive Biomarkers and Therapeutic Targets in Hepatocellular Carcinoma

Tanaka

Tateishi

Koike

2018

IJMS

View full text Add to dashboard Cite

Proteoglycans, which consist of a protein core and glycosaminoglycan chains, are major components of the extracellular matrix and play physiological roles in maintaining tissue homeostasis. In the carcinogenic tissue microenvironment, proteoglycan expression changes dramatically. Altered proteoglycan expression on tumor and stromal cells affects cancer cell signaling pathways, which alters growth, migration, and angiogenesis and could facilitate tumorigenesis. This dysregulation of proteoglycans has been implicated in the pathogenesis of diseases such as hepatocellular carcinoma (HCC) and the underlying mechanism has been studied extensively. This review summarizes the current knowledge of the roles of proteoglycans in the genesis and progression of HCC. It focuses on well-investigated proteoglycans such as serglycin, syndecan-1, glypican 3, agrin, collagen XVIII/endostatin, versican, and decorin, with particular emphasis on the potential of these factors as biomarkers and therapeutic targets in HCC regarding the future perspective of precision medicine toward the “cure of HCC”.

show abstract

“…The development of HCC is closely associated with angiogenesis ( 30 ). Endostar, a recombinant human endostatin for inhibiting angiogenesis, was developed originally for the treatment of lung cancer and was also used for HCC treatment ( 31 ). This mechanism can be achieved by inhibiting endothelial cell migration to inhibit tumor angiogenesis and to block the nutrient supply of tumor cells ( 32 ).…”

Section: Discussionmentioning

confidence: 99%

Angiogenesis for tumor vascular normalization of Endostar on hepatoma 22 tumor-bearing mice is involved in the immune response

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Tumor vascular normalization involved in immune response is beneficial to the chemotherapy of tumors. Recombinant human endostatin (Endostar), an angiogenesis inhibitor, has been demonstrated to be effective in hepatocellular cancer (HCC). However, its vascular normalization in HCC and the role of the immune response in angiogenesis were unclear. In the present study, effects of Endostar on tumor vascular normalization were evaluated in hepatoma 22 (H22) tumor-bearing mice. Endostar was able to inhibit the proliferation and infiltration of tumor cells and improve α-fetoprotein, tumor necrosis factor-α and cyclic adenosine 5′-phosphate levels in the serum of H22-bearing mice, as well as the protein expression levels of the immune factors interferon-γ and cluster of differentiation (CD)86 in liver tissue. Endostar also exhibited more marked downregulation of the levels of vascular endothelial growth factor, CD31, matrix metalloproteinase (MMP)-2, MMP-9 and interleukin-17 during day 3–9 treatment, resulting in short-term normalization of tumor blood vessels. The period of vascular normalization was 3–9 days. The results of the present study demonstrated that Endostar was able to induce the period of vascular normalization, contributing to a more efficacious means of HCC treatment combined with other chemotherapy, and this effect was associated with the immune response. It may be concluded that Endostar inhibited immunity-associated angiogenesis behaviors of vascular endothelial cells in response to HCC. The results of the present study provided more reasonable possibility for the combination therapy of Endostar for the treatment of HCC.

show abstract

Inhibitory Effect of Endostar on Specific Angiogenesis Induced by Human Hepatocellular Carcinoma

Cited by 8 publications

References 28 publications

Proteoglycans in Cancer: Friends or Enemies? A Special Focus on Hepatocellular Carcinoma

Proteoglycans in Cancer: Friends or Enemies? A Special Focus on Hepatocellular Carcinoma

Proteoglycans Are Attractive Biomarkers and Therapeutic Targets in Hepatocellular Carcinoma

Angiogenesis for tumor vascular normalization of Endostar on hepatoma 22 tumor-bearing mice is involved in the immune response

Contact Info

Product

Resources

About